Gilead Sciences, Inc.: Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease - Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research
Source: finanznachrichten.de